Sharlene Gill’s summary of KEYNOTE-811 by Yelena Janjigian from ESMO23

Sharlene Gill shared on her Twitter:

“ KN811 Yelena Janjigian: ph3 HER2+ mG/GEJc chemo + trastuzumab +/- pembro  

• n= 698, global, 85% CPS>1
• PFS 10v8m, HR 0.72
• ORR 73% v 60%, CR 17%!
• lOS 20 v15.8m, HR 0.81 in CPS> 1-bit pNS in all-comers
• addition of pembro is new SOC option in HER2+ PDL1 CPS>1 1L mG/GEJ ca “

Source: Sharlene Gill/Twitter

Dr. Sharlene Gill is a Professor of Medicine at the University of British Columbia and a medical oncologist specializing in gastrointestinal (GI) malignancies at BC Cancer – Vancouver, Canada.  Dr. Gill serves as the Chair of the Canadian Clinical Trials Group (CCTG) GI Disease Site Committee and Chair of the UBC Department of Medicine Mentoring Committee.  She is the Editor-in-Chief for Current Oncology and is the President of the Canadian Association of Medical Oncologists. Her TEDx talk in 2022 on ‘How to Flip the Script on Cancer’ delivered her passion for patient advocacy and empowerment.